{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:03:06Z","timestamp":1788814986225,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jaip.2018.04.013","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T04:28:15Z","timestamp":1530764895000},"page":"1097-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Chronic Spontaneous Urticaria: The Devil's Itch"],"prefix":"10.1016","volume":"6","author":[{"given":"Sarbjit S.","family":"Saini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen P.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.04.013_bib1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaci.2004.02.049","article-title":"Chronic urticaria: pathogenesis and treatment","volume":"114","author":"Kaplan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0190-9622(99)70495-0","article-title":"Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies","volume":"40","author":"Sabroe","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1081-1206(10)60360-2","article-title":"Effect of arterial hypertension on chronic urticaria duration","volume":"103","author":"Nebiolo","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1398-9995.2004.00473.x","article-title":"Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients","volume":"59","author":"Toubi","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2133.1969.tb16041.x","article-title":"Urticaria and angio-oedema: a review of 554 patients","volume":"81","author":"Champion","year":"1969","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0091-6749(78)90113-6","article-title":"Assessment of tissue fluid histamine levels in patients with urticaria","volume":"61","author":"Kaplan","year":"1978","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0091-6749(95)70055-2","article-title":"Mast cell number and phenotype in chronic idiopathic urticaria","volume":"96","author":"Smith","year":"1995","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0091-6749(86)90240-X","article-title":"Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells","volume":"78","author":"Elias","year":"1986","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0091-6749(99)70475-6","article-title":"Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies","volume":"103","author":"Sabroe","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib13","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/bjd.13621","article-title":"Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (\u2018idiopathic\u2019) urticaria","volume":"172","author":"Kay","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/cea.12348","article-title":"Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria","volume":"44","author":"Kay","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.iac.2013.09.012","article-title":"Chronic spontaneous urticaria: etiology and pathogenesis","volume":"34","author":"Saini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.013_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.alit.2017.09.003","article-title":"Chronic spontaneous urticaria and the extrinsic coagulation system","volume":"67","author":"Yanase","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2018.04.013_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1034\/j.1398-9995.2001.00296.x","article-title":"Mast-cell phenotype in urticaria","volume":"56","author":"Nettis","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.12991","article-title":"Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin","volume":"171","author":"Kay","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0091-6749(86)90260-5","article-title":"Increased compound 48\/80 induced local histamine release from nonlesional skin of patients with chronic urticaria","volume":"78","author":"Bedard","year":"1986","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib20","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/j.1365-2222.2010.03582.x","article-title":"Serum total tryptase levels are increased in patients with active chronic urticaria","volume":"40","author":"Ferrer","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2016.11.037","article-title":"Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures","volume":"5","author":"Doong","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.4049\/jimmunol.1300290","article-title":"Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation","volume":"192","author":"Morimoto","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/archderm.1983.01650320010007","article-title":"Association of chronic urticaria and angioedema with thyroid autoimmunity","volume":"119","author":"Leznoff","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1067\/mjd.2003.142","article-title":"Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review","volume":"48","author":"Kozel","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.013_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaci.2016.04.036","article-title":"Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Ialpha subunit","volume":"138","author":"Auyeung","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib27","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib28","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib29","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.autrev.2017.10.003","article-title":"Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review","volume":"16","author":"Kolkhir","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaip.2018.04.013_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0091-6749(92)90297-F","article-title":"Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission","volume":"89","author":"Jacques","year":"1992","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2018.04.013_bib33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clim.2009.05.003","article-title":"Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2","volume":"132","author":"Saini","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jaci.2017.07.026","article-title":"Histamine and TLR ligands synergistically induce endothelial-cell gap-formation by the extrinsic coagulating pathway","volume":"141","author":"Yanase","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib36","doi-asserted-by":"crossref","first-page":"e14794","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase\u2013a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2018.04.013_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib39","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jaip.2018.04.013_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib41","doi-asserted-by":"crossref","unstructured":"Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, et\u00a0al. IL-24 is a common and specific autoantigen of IgE in chronic spontaneous urticaria [published online ahead of print December 5, 2017]. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2017.10.035.","DOI":"10.1016\/j.jaci.2017.10.035"},{"key":"10.1016\/j.jaip.2018.04.013_bib42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaci.2006.08.043","article-title":"Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria","volume":"119","author":"Asero","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11739-009-0333-5","article-title":"Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications","volume":"5","author":"Cugno","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaip.2018.04.013_bib44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2014.11.016","article-title":"Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria","volume":"135","author":"Asero","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib45","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jaip.2017.07.009","article-title":"Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU","volume":"5","author":"Asero","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000155748","article-title":"Expression of tissue factor by eosinophils in patients with chronic urticaria","volume":"148","author":"Cugno","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib47","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2249.2011.04541.x","article-title":"Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency","volume":"167","author":"van Geffen","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/j.1398-9995.2011.02704.x","article-title":"Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation","volume":"66","author":"Bossi","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.18176\/jiaci.0051","article-title":"Detection of low-molecular-weight mast cell-activating factors in serum from patients with chronic spontaneous urticaria","volume":"26","author":"Cugno","year":"2016","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/mai.2002.120954","article-title":"A\u00a0role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria","volume":"109","author":"Kikuchi","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2222.1996.tb00628.x","article-title":"Further characterization of histamine releasing chemokines present in fractionated supernatants derived from human mononuclear cells","volume":"26","author":"Kuna","year":"1996","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.coi.2008.09.005","article-title":"New concepts in chronic urticaria","volume":"20","author":"Vonakis","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/jid.2014.16","article-title":"Basophils and skin disorders","volume":"134","author":"Borriello","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-2776(08)01004-3","article-title":"Basophils beyond effector cells of allergic inflammation","volume":"101","author":"Schroeder","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1398-9995.1962.tb02937.x","article-title":"Basophilic leucopenia in different forms of urticaria","volume":"17","author":"Rorsman","year":"1962","journal-title":"Acta Allergol"},{"key":"10.1016\/j.jaip.2018.04.013_bib57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaci.2006.09.035","article-title":"Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria","volume":"119","author":"Vonakis","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib58","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2222.2005.02212.x","article-title":"Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli","volume":"35","author":"Luquin","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib59","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/all.13215","article-title":"Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria","volume":"72","author":"Rauber","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib60","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/jid.2008.55","article-title":"Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies","volume":"128","author":"Eckman","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib61","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI108405","article-title":"Defective histamine release in chronic urticaria","volume":"57","author":"Kern","year":"1976","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2018.04.013_bib62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/all.12578","article-title":"Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria","volume":"70","author":"Oliver","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2222.2003.01589.x","article-title":"Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity","volume":"33","author":"Grattan","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib64","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2500\/aap.2011.32.3483","article-title":"Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria","volume":"32","author":"Magen","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2018.04.013_bib65","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaci.2015.06.004","article-title":"Altered expression of chemoattractant receptor-homologous molecule expressed on T(H)2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria","volume":"137","author":"Oliver","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib66","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2222.2006.02494.x","article-title":"Evidence of in\u00a0vivo basophil activation in chronic idiopathic urticaria","volume":"36","author":"Vasagar","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib67","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1398-9995.2011.02570.x","article-title":"Basophil recruitment and activation in inflammatory skin diseases","volume":"66","author":"Ito","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib68","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jid.2016.11.025","article-title":"Effect of omalizumab on blood basophil counts in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Saini","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib69","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil FcepsilonRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2018.04.013_bib70","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mai.2002.121314","article-title":"Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria","volume":"109","author":"Confino-Cohen","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/000155502320323199","article-title":"Cytokine production of CD4+ and CD8+ peripheral T lymphocytes in patients with chronic idiopathic urticaria","volume":"82","author":"Irinyi","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2018.04.013_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000058004","article-title":"Immune profiles of patients with chronic idiopathic urticaria","volume":"128","author":"Piconi","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2004.03.016","article-title":"Low stimulated IL-4 secretion in PBMC from patients with chronic idiopathic urticaria","volume":"27","author":"Confino-Cohen","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.jaip.2018.04.013_bib76","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2010.10198.x","article-title":"Impaired IFN-alpha secretion by plasmacytoid dendritic cells induced by TLR9 activation in chronic idiopathic urticaria","volume":"164","author":"Futata","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib77","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.intimp.2008.05.016","article-title":"Increased circulating pro-inflammatory cytokines and imbalanced regulatory T-cell cytokines production in chronic idiopathic urticaria","volume":"8","author":"Dos Santos","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2018.04.013_bib78","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/00015550410026939","article-title":"Chronic idiopathic and chronic autoimmune urticaria: clinical and immunopathological features of 68 subjects","volume":"84","author":"Caproni","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2018.04.013_bib79","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.humimm.2012.03.016","article-title":"Elevated serum B-cell activating factor in patients with chronic urticaria","volume":"73","author":"Kessel","year":"2012","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0625.2010.01067.x","article-title":"Increased levels of serum IL-31 in chronic spontaneous urticaria","volume":"19","author":"Raap","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib81","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1468-3083.2012.04486.x","article-title":"Acute phase inflammatory markers in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-induced acute urticaria\/angioedema and after aspirin challenge","volume":"27","author":"Kasperska-Zajac","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2018.04.013_bib82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000453453","article-title":"D-Dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria","volume":"172","author":"Asero","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib83","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaip.2018.04.013_bib84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.iac.2013.09.010","article-title":"Physical urticarias and cholinergic urticaria","volume":"34","author":"Abajian","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.013_bib85","series-title":"Urticaria and Angioedema","first-page":"251","article-title":"Diagnosis of difficult urticaria and angioedema","author":"Kaplan","year":"2009"},{"key":"10.1016\/j.jaip.2018.04.013_bib86","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaci.2008.12.008","article-title":"High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study","volume":"123","author":"Siebenhaar","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib87","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib88","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib89","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib90","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/archderm.1988.01670020048016","article-title":"Delayed pressure urticaria histologically resembles cutaneous late-phase reactions","volume":"124","author":"Mekori","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2009.02188.x","article-title":"Efficacy of omalizumab in delayed pressure urticaria: a case report","volume":"65","author":"Bindslev-Jensen","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib92","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaip.2016.09.029","article-title":"Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors","volume":"5","author":"Sanchez","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.anai.2012.02.018","article-title":"The role of autoimmune testing in chronic idiopathic urticaria","volume":"108","author":"Viswanathan","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0091-6749(89)90180-2","article-title":"Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients","volume":"84","author":"Leznoff","year":"1989","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1067\/mai.2003.1605","article-title":"Antithyroid antibodies in chronic urticaria and angioedema","volume":"112","author":"Kikuchi","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00005792-199501000-00003","article-title":"Hypocomplementemic urticarial vasculitis syndrome: clinical and serologic findings in 18 patients","volume":"74","author":"Wisnieski","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2018.04.013_bib97","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/CRIAI:23:2:201","article-title":"Urticarial vasculitis","volume":"23","author":"Venzor","year":"2002","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib98","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2018.04.013_bib99","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study","volume":"132","author":"Krause","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11882-008-0047-1","article-title":"The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies","volume":"8","author":"Glaser","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2018.04.013_bib101","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/all.12030","article-title":"How not to miss autoinflammatory diseases masquerading as urticaria","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib102","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.30105","article-title":"The emerging role of interleukin-1beta in autoinflammatory diseases","volume":"63","author":"Lachmann","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2018.04.013_bib103","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/art.40146","article-title":"Open-label, phase II study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome","volume":"69","author":"Arostegui","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2018.04.013_bib104","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2016.07.041","article-title":"Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study","volume":"139","author":"Krause","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200101000-00004","article-title":"The Schnitzler syndrome: four new cases and review of the literature","volume":"80","author":"Lipsker","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2018.04.013_bib106","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jaip.2015.04.008","article-title":"How omalizumab came to be studied as a therapy for chronic spontaneous\/idiopathic urticaria","volume":"3","author":"Kaplan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib107","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of omalizumab on patients with chronic urticaria","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib108","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib109","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jaci.2007.12.1121","article-title":"Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria patients","volume":"121","author":"Gober","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A\u00a0randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib111","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria","volume":"127","author":"Ferrer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib112","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.013_bib113","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib114","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib115","doi-asserted-by":"crossref","unstructured":"Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et\u00a0al. The EAACI\/GA(2)LEN\/EDF\/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update [published online ahead of print January 15, 2018]. Allergy. https:\/\/doi.org\/10.1111\/all.13397.","DOI":"10.1111\/all.13397"},{"key":"10.1016\/j.jaip.2018.04.013_bib116","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib117","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMcp011186","article-title":"Clinical practice. Chronic urticaria and angioedema","volume":"346","author":"Kaplan","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.013_bib118","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.anai.2014.02.014","article-title":"Therapy of chronic urticaria: a simple, modern approach","volume":"112","author":"Kaplan","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib119","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2017.10.010","article-title":"Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND-CIU study","volume":"78","author":"Casale","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib121","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib122","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jdv.14384","article-title":"Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria","volume":"31","author":"Finlay","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2018.04.013_bib123","doi-asserted-by":"crossref","first-page":"AB54","DOI":"10.1016\/j.jaci.2017.12.172","article-title":"The Urticaria Control test as a tool for monitoring chronic idiopathic\/spontaneous urticaria treatment: results from XTEND-CIU, a 48 week randomized, placebo-controlled study","volume":"141","author":"Kaplan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib124","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","article-title":"Randomized double-blind study of cyclosporin in chronic \u2018idiopathic\u2019 urticaria","volume":"143","author":"Grattan","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib126","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1398-9995.1997.tb00996.x","article-title":"Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria","volume":"52","author":"Toubi","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib127","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","article-title":"Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Vena","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib128","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1398-9995.2010.02419.x","article-title":"Cyclosporine-A in severe chronic urticaria: the option for long-term therapy","volume":"65","author":"Kessel","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2011.08.013","article-title":"Factors that predict the success of cyclosporine treatment for chronic urticaria","volume":"107","author":"Hollander","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2222.2005.02242.x","article-title":"Effects of calcineurin inhibitors on an in\u00a0vitro assay for chronic urticaria","volume":"35","author":"Marsland","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.04.013_bib131","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1523-1747.ep12499960","article-title":"Anti-inflammatory effect of cyclosporin A on human skin mast cells","volume":"98","author":"Stellato","year":"1992","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.013_bib132","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.anai.2016.06.024","article-title":"Angioedema in the omalizumab chronic idiopathic\/spontaneous urticaria pivotal studies","volume":"117","author":"Zazzali","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib133","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jaip.2017.08.035","article-title":"Omalizumab for severe chronic spontaneous urticaria: real-life experiences of 280 patients","volume":"5","author":"Vadasz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.013_bib134","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaci.2013.04.056","article-title":"Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation","volume":"132","author":"Macglashan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib135","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2014.02.005","article-title":"Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells","volume":"133","author":"Eggel","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.013_bib136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818302903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818302903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:14:38Z","timestamp":1761974078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818302903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2213219818302903"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.013","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Spontaneous Urticaria: The Devil's Itch","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}